Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells

Suyun Huang1, Corazon D Bucana, Melissa Van Arsdall

  • 1Department of Cancer Biology, Box 173, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, TX 77030, USA.

Oncogene
|April 24, 2002
PubMed

Insights

Signal transducer and activator of transcription 1 (Stat1) in tumor cells acts as a negative regulator of tumor growth and metastasis by suppressing angiogenesis. Stat1 is essential for interferon-beta

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Signal transducer and activator of transcription 1 (Stat1) activity varies in human tumors, with unclear roles in tumor progression.
  • Stat1's influence on tumor growth, angiogenesis, and metastasis requires further investigation.

Purpose of the Study:

  • To determine if Stat1 regulates tumor cell angiogenesis, growth, and metastasis.
  • To ascertain Stat1's requirement for IFN-beta's inhibition of basic fibroblast growth factor (bFGF) expression.

Main Methods:

  • Utilized Stat1 knockout tumor cells reconstituted with a Stat1 expression vector.
  • Assessed tumorigenicity, metastasis, microvessel density, and proangiogenic molecule expression in vivo.
  • Evaluated bFGF expression in vitro and in vivo following IFN-beta treatment.

Main Results:

  • Stat1 reconstitution suppressed tumor cell tumorigenicity and metastasis in mice.
  • Decreased microvessel density and reduced expression of bFGF, MMP-2, and MMP-9 were observed in Stat1-reconstituted tumors.
  • IFN-beta inhibited bFGF expression in Stat1-reconstituted cells but not in Stat1-deficient cells.

Conclusions:

  • Tumor-intrinsic Stat1 acts as a negative regulator of tumor angiogenesis, growth, and metastasis.
  • Stat1 is crucial for mediating the antiangiogenic effects of IFN-beta by inhibiting bFGF production.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...